Roche hails an­oth­er PhI­II win on Tecen­triq com­bo, re­ports promis­ing kid­ney can­cer da­ta

Roche is ped­al­ing hard from be­hind in the race for PD-1/L1 mar­ket su­prema­cy, an­nounc­ing news at mar­ket close Mon­day that it’s wrapped up yet an­oth­er promis­ing Phase III com­bo study us­ing Tecen­triq.

With heavy­weights like Mer­ck and Bris­tol-My­ers Squibb lead­ing the mar­ket, Roche $RHH­BY and its sub­sidiary Genen­tech are step­ping up their game. The lat­est Phase III study test­ed Tecen­triq with Avastin against ad­vanced or metasta­t­ic re­nal cell car­ci­no­ma or kid­ney can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER